← Back to Search

PARP Inhibitor

Tislelizumab + Pamiparib for Cancer

Phase 3
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing the long-term safety of two cancer drugs, given alone or in combination with other drugs. It includes people who have participated in a previous study.

Who is the study for?
This trial is for patients with advanced malignancies who were previously in a BeiGene study and may benefit from continued treatment. It's not for those who had severe side effects, recent serious infections, or used other cancer treatments between studies. Pregnant women and individuals with life-threatening conditions are also excluded.Check my eligibility
What is being tested?
The study tests long-term safety of Tislelizumab and/or Pamiparib alone or combined with other agents like Capecitabine, Temozolomide, etc., in participants with advanced cancers to see if they continue to help without causing new issues.See study design
What are the potential side effects?
Possible side effects include reactions at the injection site, fatigue, nausea, blood cell count changes which could lead to increased infection risk or bleeding problems. Each drug has its own profile of potential side effects that will be monitored.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of all adverse events
Secondary outcome measures
Overall survival

Trial Design

11Treatment groups
Experimental Treatment
Group I: Tislelizumab monotherapyExperimental Treatment1 Intervention
Group II: Tislelizumab and Sitravatinib Combination TherapyExperimental Treatment2 Interventions
Group III: Tislelizumab and Pemetrexed Combination TherapyExperimental Treatment2 Interventions
Group IV: Tislelizumab and Pamiparib Combination TherapyExperimental Treatment2 Interventions
Group V: Tislelizumab and Ociperlimab Combination TherapyExperimental Treatment2 Interventions
Group VI: Tislelizumab and Fruquintinib Combination TherapyExperimental Treatment2 Interventions
Group VII: Tislelizumab and Capecitabine Combination TherapyExperimental Treatment2 Interventions
Group VIII: Tislelizumab and BAT1706 Combination TherapyExperimental Treatment2 Interventions
Group IX: Sitravatinib MonotherapyExperimental Treatment1 Intervention
Group X: Pamiparib and temozolomide Combination TherapyExperimental Treatment2 Interventions
Group XI: Pamiparib MonotherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pamiparib
2017
Completed Phase 2
~750
Tislelizumab
2018
Completed Phase 3
~4260
Fruquintinib
2021
Completed Phase 3
~1680
Sitravatinib
2021
Completed Phase 2
~700
Ociperlimab
2021
Completed Phase 2
~530
BAT1706
2021
Completed Phase 3
~750

Find a Location

Who is running the clinical trial?

BeiGeneLead Sponsor
175 Previous Clinical Trials
28,514 Total Patients Enrolled
Andong Nkobena Florinas, Pharm. D.Study DirectorBeiGene
Andong Nkobena, Pharm. D.Study DirectorBeiGene

Media Library

Pamiparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04164199 — Phase 3
Cancer Research Study Groups: Tislelizumab monotherapy, Tislelizumab and Ociperlimab Combination Therapy, Tislelizumab and BAT1706 Combination Therapy, Pamiparib and temozolomide Combination Therapy, Tislelizumab and Fruquintinib Combination Therapy, Tislelizumab and Sitravatinib Combination Therapy, Sitravatinib Monotherapy, Tislelizumab and Capecitabine Combination Therapy, Pamiparib Monotherapy, Tislelizumab and Pamiparib Combination Therapy, Tislelizumab and Pemetrexed Combination Therapy
Cancer Clinical Trial 2023: Pamiparib Highlights & Side Effects. Trial Name: NCT04164199 — Phase 3
Pamiparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04164199 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the FDA's official stance on Tislelizumab 200 mg, IV?

"Tislelizumab 200 mg, IV is considered safe based on past clinical trials and data sets."

Answered by AI

How many study participants are currently enrolled?

"Unfortunately, this particular clinical trial is not seeking new participants at this time. Although, it is worth noting that there are 889 trials for Tislelizumab 200 mg, IV enrolling patients and 2443 studies actively enrolling patients with advanced malignancies."

Answered by AI

What other similar medical trials are there to this one?

"Tislelizumab 200 mg, IV has been clinically trialed 1148 times since 2002, with 889 studies currently ongoing. The first trial, 60-patient strong, completed Phase 2 in 2002. It was sponsored by Schering-Plough."

Answered by AI

What are some other notable instances of Tislelizumab 200 mg, IV being used?

"Tislelizumab 200 mg, IV was first explored in 2002 at the Memorial Sloan Kettering Cancer Center. Since then, 1148 similar trials have been completed with 889 currently active. A large number of these active studies are being conducted in Dallas, Texas."

Answered by AI

What medical conditions does Tislelizumab 200 mg, IV typically help alleviate?

"Tislelizumab 200 mg, IV is an effective treatment for progression, disease. Additionally, it can be used to treat conditions like advanced directives, ovarian cancer, and locally advanced nonsquamous non-small cell lung cancer."

Answered by AI

Are there any unfilled appointments in this clinical trial?

"Recruitment for this clinical trial has halted. The first posting was on December 19th, 2019 with the most recent update on March 4th, 2022. However, there are 2443 other trials actively recruiting patients with advanced malignancies and 889 trials for Tislelizumab 200 mg, IV that may have open enrollment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies
2019. "Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04164199.
~16 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top